Cargando…
Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy
We examined the long-term clinical tolerance and cardiac safety of trastuzumab treatment in ninety-four female patients diagnosed with breast cancer with human epidermal growth factor receptor 2 (HER-2) overexpression. Electrocardiography (ECG) was monitored throughout trastuzumab treatment, and lef...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356780/ https://www.ncbi.nlm.nih.gov/pubmed/27906683 http://dx.doi.org/10.18632/oncotarget.13726 |
_version_ | 1782515914628923392 |
---|---|
author | Huang, Ping Dai, Shujun Ye, Zhimin Liu, Yajuan Chen, Zhanhong Zheng, Yabing Shao, Xiying Lei, Lei Wang, Xiaojia |
author_facet | Huang, Ping Dai, Shujun Ye, Zhimin Liu, Yajuan Chen, Zhanhong Zheng, Yabing Shao, Xiying Lei, Lei Wang, Xiaojia |
author_sort | Huang, Ping |
collection | PubMed |
description | We examined the long-term clinical tolerance and cardiac safety of trastuzumab treatment in ninety-four female patients diagnosed with breast cancer with human epidermal growth factor receptor 2 (HER-2) overexpression. Electrocardiography (ECG) was monitored throughout trastuzumab treatment, and left ventricular ejection fractions (LVEFs) were estimated using echocardiography prior to treatment with trastuzumab and every 3 months after its first application. The duration of trastuzumab treatments ranged from 3 to 60 months. Declines in LVEF ≥ 15% were seen mainly after 3-15 months of trastuzumab treatment, and LVEF was lowest at 15 months, which coincided with the largest decline in LVEF from baseline. Spearman correlation coefficients indicated that accumulation of anthracycline, the use of cyto/cardioprotective drugs (CPD) and the duration of trastuzumab treatment were all associated with the change of LVEF, and there was a strong correlation between these factors and the change of LVEF (ρ=0.81, ρ=0.734 and ρ=0.777 respectively). These results indicate that significant decreases of LVEF may be seen after 3-15 months of trastuzumab treatment, but that there is a favorable benefit-risk ratio for patients undergoing long-term trastuzumab treatment. |
format | Online Article Text |
id | pubmed-5356780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53567802017-04-20 Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy Huang, Ping Dai, Shujun Ye, Zhimin Liu, Yajuan Chen, Zhanhong Zheng, Yabing Shao, Xiying Lei, Lei Wang, Xiaojia Oncotarget Research Paper We examined the long-term clinical tolerance and cardiac safety of trastuzumab treatment in ninety-four female patients diagnosed with breast cancer with human epidermal growth factor receptor 2 (HER-2) overexpression. Electrocardiography (ECG) was monitored throughout trastuzumab treatment, and left ventricular ejection fractions (LVEFs) were estimated using echocardiography prior to treatment with trastuzumab and every 3 months after its first application. The duration of trastuzumab treatments ranged from 3 to 60 months. Declines in LVEF ≥ 15% were seen mainly after 3-15 months of trastuzumab treatment, and LVEF was lowest at 15 months, which coincided with the largest decline in LVEF from baseline. Spearman correlation coefficients indicated that accumulation of anthracycline, the use of cyto/cardioprotective drugs (CPD) and the duration of trastuzumab treatment were all associated with the change of LVEF, and there was a strong correlation between these factors and the change of LVEF (ρ=0.81, ρ=0.734 and ρ=0.777 respectively). These results indicate that significant decreases of LVEF may be seen after 3-15 months of trastuzumab treatment, but that there is a favorable benefit-risk ratio for patients undergoing long-term trastuzumab treatment. Impact Journals LLC 2016-11-30 /pmc/articles/PMC5356780/ /pubmed/27906683 http://dx.doi.org/10.18632/oncotarget.13726 Text en Copyright: © 2017 Huang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Huang, Ping Dai, Shujun Ye, Zhimin Liu, Yajuan Chen, Zhanhong Zheng, Yabing Shao, Xiying Lei, Lei Wang, Xiaojia Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title | Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title_full | Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title_fullStr | Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title_full_unstemmed | Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title_short | Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
title_sort | long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356780/ https://www.ncbi.nlm.nih.gov/pubmed/27906683 http://dx.doi.org/10.18632/oncotarget.13726 |
work_keys_str_mv | AT huangping longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT daishujun longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT yezhimin longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT liuyajuan longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT chenzhanhong longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT zhengyabing longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT shaoxiying longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT leilei longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy AT wangxiaojia longtermtoleranceandcardiacfunctioninbreastcancerpatientsreceivingtrastuzumabtherapy |